Glory Health Industry Limited (2329) has appointed Mr. Wang Shiyu, aged 68, as an independent non-executive director, effective December 1, 2025. He will also serve as chairman of the Internal Control Committee and a member of the Audit Committee. According to the terms of his three-year letter of appointment, his annual emolument is set at HK$330,000, determined by reference to his expertise, scope of responsibilities, and prevailing market conditions.

Mr. Wang has longstanding experience in investment banking and global M&A, having participated in China’s capital markets since 1991. He has extensive background in leading company restructurings, reorganizations, listings, and global M&A transactions. Previous positions include managing director roles at Winall Investment Management Co., Ltd. and the investment banking department at Vantone Group.

Following the resignation of the former independent non-executive director on June 10, 2025, the company applied to the Stock Exchange on September 9, 2025, for waivers from strict compliance with the relevant rules, though approval is still pending. With Mr. Wang’s appointment, the board now satisfies the requirements set out under Rules 3.10(1), 3.10A, and 3.21 of the Listing Rules for the composition of independent non-executive directors and the Audit Committee.